Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid

Pfizer sued Metsera and Novo Nordisk, alleging Metsera breached its merger agreement by deeming Novo's $8.5 billion bid superior. Pfizer seeks to block Metsera's termination and ensure its own deal proceeds, having received early antitrust clearance. The legal battle highlights a competition for Metsera's promising obesity drug pipeline.